Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

Delaware-based AirNexis will develop, produce, and commercialize HSK39004, a dual inhibitor that can improve airflow ...

Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...

For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...

Recent medical research reveals promising developments in the treatment of patients suffering from both diabetes and chronic obstructive pulmonary disease. The study, involving nearly 394,000 adults, ...

The Food and Drug Administration on Friday rejected Sunovion Pharmaceuticals’ treatment for chronic obstructive pulmonary disease. The late-stage drug is intended to serve as a long-term treatment for ...